Myelodysplastic Syndromes and del(5q) Disease
Associazione Qol-One funds clinical research in myelodysplastic syndromes, with a specific focus on del(5q) disease and lower-risk forms defined by IPSS-R categories. The sponsored trials address patients with limited prior treatment options and ongoing bone marrow failure.
- Lower-risk MDS
- del(5q) subtype
- Bone marrow blast count
The research landscape includes patients with very low, low, and intermediate risk disease, reflecting a therapeutic interest in clinically significant but less advanced myelodysplastic conditions.
Anemia and Red Blood Cell Transfusion Dependence
The sponsor supports studies centered on anemia associated with myelodysplastic syndromes, especially in individuals who require ongoing red blood cell transfusions. This area includes patients with persistent symptomatic burden and limited hematologic recovery.
- Transfusion-dependent anemia
- RBC transfusion independence
- Hematologic response
Clinical interest extends to improving erythroid support and reducing the need for repeated transfusion care in this population.
Thrombocytopenia in Myelodysplastic Syndromes
Associazione Qol-One also funds research into thrombocytopenia linked to lower- and intermediate-risk myelodysplastic syndromes. This reflects attention to platelet-related complications that contribute to bleeding risk and broader hematologic instability.
- Platelet response
- Long-term safety
- Hematologic support
The therapeutic scope includes treatment strategies aimed at restoring or sustaining platelet counts in patients with chronic marrow dysfunction.
Refractory and Treatment-Intolerant Patient Populations
The sponsor’s clinical research interest includes patients who are refractory, resistant, or intolerant to prior therapies, particularly ESA and lenalidomide. These studies focus on individuals with unmet needs after standard treatment exposure.
- Prior treatment failure
- Therapy intolerance
- Supportive hematology care
This area emphasizes clinical research in patients requiring alternative approaches for marrow failure–related cytopenias.
